| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARWR | Common Stock | Options Exercise | $760K | +146K | +3.61% | $5.19* | 4.2M | Feb 11, 2022 | Direct | F1 |
| transaction | ARWR | Common Stock | Sale | -$2.17M | -40.9K | -0.97% | $53.11 | 4.16M | Feb 11, 2022 | Direct | F1, F2 |
| transaction | ARWR | Common Stock | Sale | -$2.2M | -42.2K | -1.01% | $52.28 | 4.12M | Feb 11, 2022 | Direct | F1, F3 |
| transaction | ARWR | Common Stock | Sale | -$3.13M | -61.5K | -1.49% | $50.90 | 4.06M | Feb 11, 2022 | Direct | F1, F4 |
| transaction | ARWR | Common Stock | Sale | -$96K | -1.9K | -0.05% | $50.51 | 4.06M | Feb 11, 2022 | Direct | F1, F5, F6 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARWR | Stock Option (right to buy Common Stock) | Options Exercise | $0 | -146K | -19.23% | $0.00 | 615K | Feb 11, 2022 | Common Stock | 146K | $5.19 | Direct | F7, F8 |
| Id | Content |
|---|---|
| F1 | The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.63 to $53.61, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.60 to $51.61, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.58 to $51.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.49 to $50.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F6 | Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole. |
| F7 | Represents first vesting date. Option vested over four years from date of grant. |
| F8 | Represents total stock options beneficially owned at various strike prices. |